What is Clarivate's latest dividend and current dividend yield?

What were the key takeaways from Clarivate’s earnings call?

What does Clarivate do and what are its main business segments?

What is the market's earnings forecast for Clarivate next quarter?

Did Clarivate beat or miss consensus estimates last quarter?

What factors drove the changes in Clarivate's revenue and profit?

What guidance did Clarivate's management provide for the next earnings period?

What is Clarivate's gross profit margin?

- **2025 Performance**: 2% organic ACV growth, $365M free cash flow, and 88% recurring revenue mix.
- **AI Innovation**: 12 new AI products launched, 97% revenue from proprietary assets.
- **Strategic Shift**: Initiated LS&H sale to focus on A&G/IP, guiding to 2-3% 2026 ACV growth.
- **Financial Health**: $400M 2026 free cash flow (+10%), 43% EBITDA margin, and $0.75 EPS.
- **IP Recovery**: 200bps ACV improvement in 2025, new AI tools driving trademark and patent growth.


**【CEO Summary Section】**
- Clarivate delivered 2025 results with 2% organic ACV growth, 88% recurring revenue mix, and $365 million free cash flow. 
- Launched 12 major AI-powered products, including AI research assistants and workflow agents, driving 97% revenue from proprietary assets.
- Initiated process to sell Life Sciences & Health (LS&H) business to focus on Academia & Government (A&G) and Intellectual Property (IP) segments.
- 2026 guidance: 2-3% organic ACV growth, 1-2% recurring revenue growth, and $400 million free cash flow (+10%).

**【CFO Financial Commentary】**
- Q4 2025 revenue: $617 million (FY25: $2.455 billion), net income: $3 million (FY25: $195 million improvement vs. 2024).
- Adjusted EBITDA: $1.02 billion (FY25: $1.02 billion), free cash flow: $365 million (+2% vs. FY24).
- 2026 outlook: $2.36 billion revenue (-$100M from LS&H divestitures), 43% adjusted EBITDA margin, $0.75 EPS (+9%).
- Capital allocation: $225M share buybacks in 2025, $100M debt prepayments, and potential LS&H sale proceeds.

**【Q&A Key Highlights】**
- **AI Monetization**: 93% renewal rates, AI adoption in 11,000+ Life Science users, and new AI-native products like RiskMark for trademarks.
- **LS&H Sale**: Expected to strengthen balance sheet; 2026 guidance assumes ownership throughout the year.
- **IP Turnaround**: 200bps ACV improvement in 2025, new products (e.g., Derwent Patent Monitor) driving growth, and 2-3 year lag in annuity market recovery.
- **Capital Allocation**: Prioritizing debt reduction (net leverage ~4x) over buybacks, despite 30% free cash flow yield.
- **Price Realization**: 2025 growth driven by volume (renewals, new subscriptions), not price increases.


Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript

- **Operational Momentum**: 1.6% ACV growth, 93% renewal rate, and $115M share buybacks highlight execution of Value Creation Plan.
- **Segment Strengths**: A&G subscription mix at 93%, IP AI tools like Derwent Patent Monitor driving recovery, LS&H launching 12+ AI products.
- **Financial Update**: Raised 2025 revenue guidance to $2.44B, free cash flow of $340M expected, with 2026 strategic exits reducing transactional headwinds.
- **Growth Catalysts**: AI-native products (e.g., Web of Science Research Intelligence) targeting 2026, IP market recovery, and 88% recurring revenue mix.

**【CEO Summary Section】**
- **Value Creation Plan Progress**: ACV growth of 1.6% (up 30bps QoQ), 93% renewal rate (+100bps YoY), and $115M share buybacks year-to-date.
- **Segment Highlights**: 
  - **A&G**: 2% ACV growth, 93% subscription mix, 100+ contracts for new content frameworks.
  - **IP**: Flat YoY recurring revenue, 3% improvement in organic growth rate, AI tools like Derwent Patent Monitor and IPfolio launched.
  - **LS&H**: 2% ACV growth, new products like DRG Commercial Analytics 360 and AI-powered regulatory assistant.
- **Strategic Exits**: Completed exit from A&G transactional book sales and LS real-world data resale market.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: 
  - Revenue: $623M (flat YoY), Net Loss: $28M (improved vs. prior year due to FX gains).
  - Adjusted EPS: $0.18 (flat QoQ), Free Cash Flow: $181M.
- **Year-to-Date**: 
  - Organic growth improved by 160bps, Recurring Revenue Mix: 88% (vs. 80% 2024).
  - Free Cash Flow: $276M (vs. $240M prior year), $150M shares repurchased.
- **Updated Guidance**: 
  - Revenue: $2.44B (midpoint, +$50M), Adjusted EBITDA: high end of range.
  - Strategic disposals to reduce 2026 revenue by ~$100M, offset by organic growth.

**【Q&A Highlights】**
- **IP Segment Recovery**: 
  - 2025 YoY recurring revenue flat vs. -3% 2024, driven by new products and market recovery.
  - AI tools like Derwent Patent Search and IPfolio expected to drive future growth.
- **AI Product Innovation**: 
  - AI-native products (e.g., Web of Science Research Intelligence) targeting 2026 launch with 20+ contracts secured.
  - AI integration in existing workflows improving retention and efficiency.
- **Transactional Revenue Impact**: 
  - Q3 2025 saw $20M+ e-book sales, delaying exit of transactional business by ~$100M to 2026.
  - Long-term focus on 88% recurring revenue mix to enhance predictability.
- **Long-Term Growth Outlook**: 
  - A&G: 3-4% market growth achievable through subscription model.
  - IP: Returning to 4-5% growth with new product pipeline.
  - LS&H: Higher growth driven by AI-enabled solutions.


Clarivate Plc (CLVT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 organic ACV +1.3% YoY, H1 recurring revenue mix 88% (vs. 80% prior year).
- **AI Success**: 4,800 institutions adopt AI tools; IP patent annuity growth resumes after 3-year decline.
- **Financial Health**: 41% EBITDA margin, $161M H1 free cash flow, $100M share buybacks.
- **Strategic Shifts**: Disposing $125M non-core business; 80% A&G revenue now recurring.
- **Risk Mitigation**: 75% of 2025 A&G subscriptions renewed by Q3, 96% renewal rate despite U.S. funding cuts.

**【CEO Opening Remarks】**
- Q2 2025: Organic ACV grew 1.3% YoY, with A&G, IP, and Life Sciences & Health segments all showing improvement.
- Adjusted EBITDA margin expanded 50bps to 41% in H1, driven by cost efficiencies.
- Free cash flow of $50M in Q2 and $161M in H1, with 88% of organic recurring revenue mix (vs. 80% last year).
- AI-driven product innovation: 4,800 institutions adopted AI tools; Agentic AI agents launched for literature reviews.
- IP segment rebound: Patent annuity revenue growth after multi-year decline; AI-related patent filings up 5x YoY.
- Life Sciences: Cortellis product adoption driving R&D spending stability.

**【CFO Financial Commentary】**
- Q2 revenue: $621M (H1: $1.2B), net loss $72M (vs. $133M YoY due to non-recurring impairment).
- Adjusted EPS: $0.18 (H1: $0.36), with 1% organic growth in H1 (vs. -1.8% YoY).
- Free cash flow conversion: 34% of adjusted EBITDA, with $100M share buybacks in H1.
- 2025 Outlook: Organic ACV growth ~1.5%, adjusted EBITDA ~$230M, free cash flow ~$340M.
- Strategic disposals: $125M revenue impact in 2025, with 80% of A&G revenue now recurring.

**【Q&A Highlights】**
- **IP Business Growth**: AI-related patent filings up 5x YoY; China driving 60% of global AI patent growth. Renewal pipeline improving for 2026.
- **University Funding Risks**: 75% of 2025 A&G subscriptions renewed by Q3, with 96% renewal rate. Shift to subscription e-books mitigates budget cuts.
- **Sales Momentum**: Simplified sales incentives focused on subscriptions; 70+ e-book wins in H1.
- **Life Sciences Recovery**: R&D spending stable, commercial spending lagging. Cortellis AI tools improving customer retention.
- **Debt Management**: $200M debt repayment; $0.5B debt refinanced to 2031 with 80% hedged to EUR.


Clarivate Plc (CLVT) Q2 2025 Earnings Call Transcript

- **Revenue Mix Shift**: Recurring revenue now 83% of total (vs. 81% last year), driven by subscription model success.
- **AI Growth Engine**: Double-digit search volume growth in Derwent and 3,000+ institutions using AI tools.
- **Government Risk Mitigation**: <3% revenue directly tied to US federal government; risk analysis shows 2025 impact within guidance.
- **Patent Market Recovery**: 5% YoY growth in IP annuity revenue, signaling stabilization post-pandemic decline.
- **Free Cash Flow Strength**: $110M Q1 free cash flow, with $340M annual target supported by cost savings and share buybacks.
- **Key Risks**: Transactional revenue expected to decline 2-3% YoY, but offset by recurring growth and strategic cost cuts.

**【CEO Summary Section】**
- **Organic ACV Growth**: Sequential improvement driven by higher renewal rates (+1%) and new business wins, with recurring revenue mix rising to 83% (vs. 81% last year).
- **AI Adoption**: Over 3,000 customers across 90+ countries using AI-powered research tools, with Derwent search volume up double-digit YoY.
- **Government Risk Management**: <3% revenue directly tied to US federal government; comprehensive risk analysis shows impact contained within guidance range.
- **Patent Annuity Recovery**: Organic recurring revenue +5% QoQ due to higher volumes, signaling market stabilization.
- **Cross-Segment Wins**: Multi-million dollar renewal with Brazilian consortium, showcasing ability to bundle solutions across segments.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: 
  - Total revenue: $594M (YoY decline due to strategic divestitures)
  - Adjusted EBITDA: $220M (1.1% margin expansion)
  - Free cash flow: $110M
  - Shares repurchased: 11.7M ($50M)
- **Full Year Outlook**: 
  - Recurring revenue mix to improve to 85% (from 80%)
  - Adjusted EBITDA: $940M-$1B (41.5% margin)
  - Free cash flow: $340M
- **Key Drivers**: 
  - $100M+ cost savings offset $140M revenue loss from divestitures
  - 5% recurring revenue mix improvement
  - $20M interest expense reduction

**【Q&A Highlights】**
1. **A&G Segment Risk**: 
   - <50% of A&G revenue tied to US universities
   - 50%+ government contracts already renewed
   - Customer advisory groups indicate cautious but stable budgets
2. **IP Renewal Sustainability**: 
   - 5.3% organic growth driven by volume recovery
   - Lagged impact of patent in-force data suggests long-term stability
3. **Strategic Disposals Impact**: 
   - $140M revenue reduction offset by $100M cost savings
   - Remaining $60M impact deferred to 2026
4. **Sales Incentive Model**: 
   - Rebalanced to reward subscription growth and customer retention
   - New leadership in IP, A&G, and Life Science sales
5. **AI Product Pipeline**: 
   - Q2 launch of AI agents in Web of Science
   - Agentic AI integration across segments in H2 2025

Clarivate (CLVT)-29 Apr 25-2025 Q1 Earnings call transcript

- **VCP Strategic Shift**: Transitioning $200M+ transactional revenue to subscription, boosting recurring mix to 87% and margin by 150bps.
- **AI Innovation Payoff**: Academic AI Platform expansion into Life Sciences/IP, with ~$200M+ pipeline for 2026+.
- **2025 Financial Targets**: ACV growth 1.5%, EBITDA $940M-$1B, free cash flow $340M, despite $140M revenue headwind from disposals.
- **Government Risk Mitigation**: <10% revenue directly tied to U.S. gov funding; focused on subscription resilience.
- **Sales Execution Reset**: 80%+ of sales comp tied to recurring metrics, driving subscription focus.


**【CEO Summary Section】**
- Clarivate announced a Value Creation Plan (VCP) to return to organic growth, focusing on four pillars: revenue optimization, sales execution acceleration, innovation, and portfolio rationalization.
- Key strategic moves include transitioning ProQuest e-Books and Digital Collections to subscription-only models by end-2025, exiting high-risk real-world data brokering, and winding down transactional books business.
- These changes aim to increase recurring revenue mix from 80% to 87%, improve gross margin by 150bps, and reduce volatile transactional revenue by $200M.
- CEO emphasized the importance of AI-driven product innovation, with examples like Academic AI Platform in A&G, DRG Fusion in Life Sciences, and Derwent AI in IP.
- Strategic alternatives evaluation may include divesting business units or segments to unlock value.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $663M (full year: $2.56B), with organic decline improving to 0.7% Q4 vs. 1.5% YTD.
- Adjusted EBITDA: $940M-$1B (2025 guidance), maintaining 41.5% margin through cost control.
- Free cash flow: $340M midpoint (2025), driven by lower capex ($35M reduction) and improved conversion.
- 2025 ACV growth expected to accelerate to 1.5% midpoint, with recurring revenue mix rising to 85%.
- Strategic disposals will reduce 2025 revenue by ~$140M but yield $100M cost savings, offsetting 70% of profit impact.

**【Q&A Key Highlights】**
- **Government Exposure**: <10% of revenue directly tied to U.S. federal/state funding; optimistic about academia's long-term resilience.
- **Sales Incentives**: Rebalanced to prioritize subscription/recurring sales, with 80%+ of compensation tied to recurring metrics.
- **Patent Renewals**: Q4 decline due to timing; 2025 focus on improving retention via better customer engagement and AI tools.
- **AI Investment**: Academic AI Platform being repurposed for Life Sciences (Cortellis) and IP (Derwent AI), with ~$200M+ pipeline for 2026+.
- **Strategic Review**: Evaluating monetization of undervalued assets; potential criteria include standalone viability, market demand, and accretion potential.


Actual				0.07	0.18	0.14	0.22	0.14	0.17	0.16	0.23	0.21	0.22	0.2	0.22	0.18	0.21	0.21	0.23	0.14	0.2	0.19	0.21	0.14	0.18	0.18	0.2
Forecast				0.0912	0.1416	0.1513	0.166	0.1199	0.1705	0.1548	0.2112	0.1757	0.2053	0.1734	0.1719	0.1535	0.1933	0.1833	0.2107	0.1391	0.1812	0.1856	0.2026	0.1157	0.1737	0.1582	0.164
Surprise	0.00%	0.00%	0.00%	-23.25%	+27.12%	-7.47%	+32.53%	+16.76%	-0.29%	+3.36%	+8.90%	+19.52%	+7.16%	+15.34%	+27.98%	+17.26%	+8.64%	+14.57%	+9.16%	+0.65%	+10.38%	+2.37%	+3.65%	+21.00%	+3.63%	+13.78%	+21.95%

CLVT

CLVT fundamentals

CLVT Q4 2025 Earnings

Earnings Call

You can ask Aime

CLVT

CLVT fundamentals

CLVT Q4 2025 Earnings

Earnings Call

CLVT Earnings Call Summary for Q4/20259:00 AM on Feb 24, 2026

CLVT Earnings Call Summary for Q3/20259:00 AM on Oct 29, 2025

CLVT Earnings Call Summary for Q2/20259:00 AM on Jul 30, 2025

CLVT Earnings Call Summary for Q1/20259:00 AM on Apr 29, 2025

CLVT Earnings Call Summary for Q4/20249:00 AM on Feb 19, 2025

You can ask Aime